Drug Development

Phase 1 Trials Lepodisiran Eli Lilly Therapeutic Targets

DKK1 Blockade Reverses Immune Resistance in Bone Metastases

Trials of the DKK1-blocking antibody DKN-01 guided by CHI3L3 biomarker research follow preclinical results that reactivated T cells against bone tumors.

4 ARTICLES

last mo.

Astrocyte-Derived Peptide Achieves Nausea-Free Weight Loss in Animal Models

3 ARTICLES

3mo ago

Illusia Probe Maps Signaling That Drives Breast Cancer Cell Invasion

7 ARTICLES

5mo ago

Eli Lilly’s Lepodisiran Achieves 94% Reduction in Genetic Heart Disease Risk Factor in Phase 2 Trial

11 ARTICLES

last yr.

Novo Nordisk's Amycretin Pill Shows Promising Weight Loss Results in Early Trial